Scarica l'app Stockscreener
0.34
12.92%
0.0389
Precedente Chiudi:
$0.3011
Aprire:
$0.295
Volume 24 ore:
320.32K
Relative Volume:
0.63
Capitalizzazione di mercato:
$12.54M
Reddito:
-
Utile/perdita netta:
$-117.67M
Rapporto P/E:
-0.11
EPS:
-3.09
Flusso di cassa netto:
$-101.06M
1 W Prestazione:
+12.21%
1M Prestazione:
+12.47%
6M Prestazione:
-40.66%
1 anno Prestazione:
-86.77%
Intervallo 1D:
$0.295
$0.35
Intervallo di 1 settimana:
$0.2854
$0.35
Portata 52W:
$0.2195
$3.67
Athira Pharma Inc Stock (ATHA) Company Profile
Nome
Athira Pharma Inc
Settore
Industria
Telefono
(425) 620-8501
Indirizzo
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Confronta ATHA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.34 | 12.54M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-19 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-09-04 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-09-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | Iniziato | Rodman & Renshaw | Buy |
| 2022-10-17 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-06-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | Downgrade | Jefferies | Buy → Hold |
| 2022-06-23 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Iniziato | BTIG Research | Buy |
| 2022-04-21 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Goldman | Neutral |
| 2020-10-13 | Iniziato | Goldman | Buy |
| 2020-10-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-13 | Iniziato | Jefferies | Buy |
| 2020-10-13 | Iniziato | Stifel | Buy |
Mostra tutto
Athira Pharma Inc Borsa (ATHA) Ultime notizie
Investors Can Still File Late Claims in Athira Pharma Settlement — Here’s How to Get Your Share - TradingView
Two Sigma Advisers LP Has $149,000 Position in Athira Pharma, Inc. (NASDAQ:ATHA) - Defense World
ATHA LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Athira Pharma, Inc. Investors with LARGE LOSSES to Secure Counsel Before Important Deadline in Securities Class Action – ATHA - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Athira Pharma (NASDAQ:ATHA) Trading 9.2% Higher – Here’s Why - Defense World
HAGENS BERMAN, NATIONAL ATTORNEYS, Alerts Athira Pharma (ATHA) Investors to Filing Of Securities Class Action, Advises Investors with Losses to Contact Firm's Attorneys Now - ACCESS Newswire
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022 - Barchart.com
Athira Pharma Holds Annual Stockholders Meeting - TipRanks
Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022 - Barchart.com
This Athira Pharma Insider Increased Their Holding By 111% Last Year - Yahoo Finance
Athira Pharma (ATHA) Is Paying a $10M Settlement to Investors — Here’s How to Get Your Share - TradingView
Athira Pharma’s SWOT analysis: als drug developer’s stock faces pivotal phase - Investing.com
Athira Pharma (ATHA) Highlights Promising Phase 1 Results for ALS Drug Candidate | ATHA Stock News - GuruFocus
Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 - Yahoo Finance
Athira Pharma (ATHA) Projected to Post Earnings on Wednesday - Defense World
Athira Pharma Reports Reduced Losses and Strategic Focus - MSN
Athira Pharma to Present Data from First-in-Human Phase 1 Clinic - GuruFocus
Athira Pharma to Present Data from First-in-Human Phase 1 - GlobeNewswire
Breakthrough ALS Drug ATH-1105 Achieves Key Safety Milestones, Targets Patient Trials Late 2025 - Stock Titan
Athira Pharma Reports First Quarter 2025 Financial Results and P - GuruFocus
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates - The Manila Times
Athira Pharma, Inc. (NASDAQ:ATHA) Position Lowered by Renaissance Technologies LLC - Defense World
Athira Pharma Slides As Insider Purchases Lose Another US$89k - simplywall.st
Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World
ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan
Athira Pharma shifts to Nasdaq Capital Market amid compliance bid By Investing.com - Investing.com India
Athira Pharma shifts to Nasdaq Capital Market amid compliance bid - Investing.com Australia
Athira Pharma stock plunges to 52-week low of $0.25 - Investing.com Australia
Athira Pharma stock plunges to 52-week low of $0.25 By Investing.com - Investing.com South Africa
SEC Form PRE 14A filed by Athira Pharma Inc. - Quantisnow
Athira Pharma stock hits 52-week low at $0.3 amid steep decline - Investing.com India
Athira Pharma stock hits 52-week low at $0.3 amid steep decline By Investing.com - Investing.com South Africa
What is ATHA’s price-to-sales ratio telling us about the company’s value? - US Post News
Athira Pharma: Hold Rating Amid Strategic Uncertainty and Resource Challenges - TipRanks
Athira Pharma stock hits 52-week low at $0.33 amid steep decline - Investing.com India
Athira Pharma stock hits 52-week low at $0.33 amid steep decline By Investing.com - Investing.com South Africa
Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga
Athira Pharma’s Strategic Focus on ATH-1105 Amidst Uncertainties: Hold Rating Maintained - TipRanks
Athira Pharma’s 2024 Financial Results and Pipeline Progress - MSN
Athira Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates - GlobeNewswire
Athira Pharma, Inc. SEC 10-K Report - TradingView
Athira Pharma stock hits 52-week low at $0.41 amid steep decline - Investing.com Australia
Athira Pharma stock hits 52-week low at $0.41 amid steep decline By Investing.com - Investing.com South Africa
Athira Pharma Inc Azioni (ATHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Athira Pharma Inc Azioni (ATHA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
168,901 |
| Litton Mark James | President and CEO |
Jun 30 '25 |
Option Exercise |
0.00 |
108,334 |
0 |
350,925 |
| Litton Mark James | President and CEO |
Jul 01 '25 |
Sale |
0.29 |
25,123 |
7,374 |
325,802 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jun 30 '25 |
Option Exercise |
0.00 |
46,666 |
0 |
82,507 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jul 01 '25 |
Sale |
0.29 |
10,842 |
3,182 |
71,665 |
| Worthington Mark | General Counsel and CCO |
Jun 30 '25 |
Option Exercise |
0.00 |
36,666 |
0 |
120,401 |
| Worthington Mark | General Counsel and CCO |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
111,875 |
| Renninger Robert | SVP, Finance and Accounting |
Jun 30 '25 |
Option Exercise |
0.00 |
12,359 |
0 |
112,083 |
| Renninger Robert | SVP, Finance and Accounting |
Jul 01 '25 |
Sale |
0.29 |
2,897 |
850 |
109,186 |
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):